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AnalysisScience for Sale:
Academic Meets IndustryAs research becomes increasingly interdisciplinary and the lines
between academic and industrial pursuits blur, scientists on both
sides of the fence are developing outsourcing models to build
innovative collaborations and open funding opportunities.When Hurricane Katrina hit the Gulf
Coast, newly minted Tulane University
assistant professor Thomas Voss
suddenly found himself without a home,
without a lab, without even his university
e-mail account. Voss had just moved
to Tulane from Southern Research, a
contract research organization (CRO)
commonly hired by pharmaceutical and
biotech companies to complete specific
portions of research projects that the
client cannot handle internally. In the
face of the natural disaster, Voss returned
to what he knew.
He set out with his family for 6 months
as what he calls a ‘‘lab on the road.’’ He
teamed up with researchers that he
knew from his time at Southern Research
on various projects related to his
background in viral therapeutics. For
instance, he set up in vitro screens for
treatments under development and
taught researchers how to harvest mouse
lungs for virology in vivo studies.
Now, 7 years later, he has recovered his
lab space and secured grant funding—he
later found out that he had secured
an NIH grant the day of the hurricane,
but the letter was lost in the mail in
the storm’s aftermath —but he also main-
tains the relationships that he built in
those post-Katrina months. As a result,
his lab is an unorthodox but successful
hybrid: he spends the majority of his
time conducting traditional grant-funded
basic research, but he also offers his
expertise as a fee-for-service contract
researcher for both academic and indus-
trial clients.
This arrangement offers access to a
large potential funding base that most of
his academic colleagues do not tap into,
which offers a huge advantage given the
competition for grant money.‘‘In academics, the interest is always in
getting NIH grants, but the truth is, a lot of
the money—as science is changing—is
not in grants,’’ Voss says. ‘‘The money is
in different places now than it used to be.’’
But it’s not just about the money. Voss
is genuinely enthusiastic about the
science behind his contract projects and
the directions it can take his work. For
example, with his industrial clients, he
says, ‘‘we get to do really great work for
companies that have a product that needs
to be developed, and we get to do the
basic research around it.’’
His contract work is also quite varied.
He has relatively small, focused projects
but also long-term relationships with
clients that involve major intellectual
contributions from both partners.
Client or Collaborator?
These larger projects challenge the
boundary between a contractor and
a true collaborator. ‘‘It’s almost impos-
sible to think of it in any other way than
acollaboration,’’ saysPat Iversen, a senior
vice president at AVI BioPharma and one
of Voss’s clients, who has worked with
him since he began at Tulane.
Rather than a strictly business arrange-
ment, these flexible interactions between
academic and industrial scientists allow
researchers to come together in new,
more efficient ways. Both sides can often
reach a solution more quickly and prob-
ably gain greater insight than if they had
each tried to go it alone.
These types of contract-collaboration
relationships are likely to become more
common as some academic and indus-
trial research goals begin to converge.
‘‘Today in academia, there’s a large
push todomore industrial-type research,’’
says Emilio Esposito, founder of aCellcomputational chemistry and biochem-
istry consultancy called exeResearch.
‘‘Bringing someone in helps everyone
because it gets the work moving.’’
Esposito believes that the rising inter-
disciplinary nature of modern science
may be driving an increase in consulting
and outsourcing. This trend is already
apparent in commercial research. In
a 2011 poll of members of BayBio,
a nonprofit association for biosciences in
Northern California, 67% of respondents
from pharmaceutical and life science
companies reported that they expect
their outsourcing needs to increase in the
future.
This trend may also be expanding
beyond the traditional industry-CRO rela-
tionship and affect academic research,
as suggested by the rise of online services
likeScienceExchangeandZombal, scien-
tific ‘‘marketplaces’’ intended to allow
scientists to find external researchers to
conduct specific experiments. These
web sites are friendly to academic and
commercial researchers alike, which may
help open the door for academics to find
the expertise and rapid results they need
from outside the academy, rather than
from the professor in the office next door.
And outsourcing does not have tomean
completely ceding control of the project
or giving up the opportunity for further
intellectual involvement and develop-
ment. For Esposito, a crucial part of his
job is education. When he’s working on
a project for a lab, he says, ‘‘I don’t just
do the work—I also teach the student
what’s going on so they don’t need me
for the next project.’’
Like Voss, Esposito challenges conven-
tional expectations about the relationship
between researchers and paid out-
sourcers.
‘‘There’s a distinction between what
people see as a consultant versus a
collaborator,’’ Esposito says. ‘‘A consul-
tant is someone they just hand the work
over to and then take the results from. A
collaborator is someone they work with
more closely.’’ How does he view his
role? ‘‘I definitely see myself as more of
a collaborator,’’ he says.
New Funding, New Frontiers
Sometimes, though, researchers don’t
actually want a collaborator, even if they
don’t know it.150, July 20, 2012 ª2012 Elsevier Inc. 239
When the Dana-Farber Cancer Institute
in Boston identified a gap in their bioinfor-
matics expertise, their first thought was
to hire several professors in the area,
including John Quackenbush, a professor
of computational biology and bioinfor-
matics, who quickly pointed out the flaw
in their strategy.
‘‘Biologists now are drowning in data,
and computational biologists want to
analyze the data,’’ Quackenbush asserts.
‘‘But computational biologists don’t want
to do it for you [the biologists]—they
want to do it for themselves.’’
His colleagues, he felt, were ‘‘asking us
to do service, not science.’’ The analogy,
he says, would be if he asked them to
run thousands of PCRs for him. Though
that could be a very valuable service and
requires a specific skill set, it is not
a collaboration.
Instead of investing in more faculty who
would be interested in building collabora-
tions, but not providing services, he
proposed that Dana-Farber set up
a core facility to provide the needed
services. The result is the Center for
Cancer Computational Biology (CCCB),
equipped with researchers from techni-
cians to experienced scientists who
provide expert fee-for-service bioinfor-240 Cell 150, July 20, 2012 ª2012 Elsevier Inmatic analysis, as well as assistance
with experimental design and data collec-
tion as needed.
Quackenbush spends about 10% of his
time running the center, which is
embedded in his research group but has
its own dedicated staff. This hybrid set-
up means that clients get their results
quickly (as opposed to requests for
collaboration, which can end up on the
shelf for months or years), the CCCB
scientists benefit from the expertise of
Quackenbush’s lab, and Quackenbush
can pursue his researchwhile also helping
his academic colleagues.
‘‘It allows me to focus on the research
questions that motivate me and has al-
lowed me to come up with a good
compromise to meet the needs of the
people here without sacrificing my own
career,’’ Quackenbush said.
It seems to be working for the clients as
well. The center completed $850,000
worth of business in 2011 and is rapidly
growing to include clients in Seattle,
Canada, and Russia.
The original proposal for the center sug-
gested that it should be funded by grant
money, an approach that Quackenbush
says was ‘‘doomed to fail.’’ Aside from
the huge amount of time he would havec.had to spend just writing grants, he also
felt that it was important for researchers
to have a financial investment in the
process to improve the efficiency and ulti-
mately accelerate the research.
‘‘If something is free, people don’t value
it,’’ Quackenbush said. ‘‘If they’re not
paying for it, it’s a never-ending process
of failures and trying again.’’ Paying for
the CCCB’s work, on the other hand, ulti-
mately serves both the researcher and the
center.
And in many cases, the CCCB scien-
tists get involved in projects beyond
simply providing a service, to the extent
that, in some cases, it is appropriate for
them to share authorship on papers,
again blurring the line between contractor
and collaborator.
For CCCB, as well as Voss and Espo-
sito, it’s really about finding a way to get
the research performed well, regardless
of labels or the norms by which research
has traditionally been conducted. Their
innovative blends of academic and indus-
trial, and collaborator and contractor,
provide appealing examples for re-
evaluating how research can best be
completed and the good that can come
from looking for creative solutions to
ever-changing challenges.Rachel Bernstein
San Francisco, CA
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